10月6日 - ** 制药商吉利德科学公司GILD.O股价盘前攀升4.1%至117.28美元
** 公司称已解决了与印度制药商Lupin、Cipla和Laurus Labs的专利诉讼，这些制药商曾为吉利德的HIV药物Biktarvy的仿制药提出上市申请。
** GILD 公司称，预计在 2036 年 4 月 1 日之前，某些药物的仿制药不会进入美国市场。
** 截至收盘，GILD 公司股价累计上涨 22
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.